EXoPERT EMERALD Clinical Study

Inclusion Criteria:

• Subject aged 45 years or older with a biopsy-proven or clinically suspected primarylung, breast, colorectal, pancreatic, or ovarian cancer, based on objective findingssuch as radiological, serological, endoscopic, or cytological findings, whose bloodwas collected prior to any systemic or definitive therapy for the cancer.

• Subjects who are willing and able to provide written informed consent.

• Subjects who are willing and able to comply with the study requirements.

Exclusion Criteria:

• Any history of cancer diagnosed and treated within 5 years prior to the date ofconsent.

• Subjects with a history of previous cancer treatment via surgical resection,hormonal cancer treatment, chemotherapy, radiotherapy within the past 6 months forrecent cancer diagnosis.

• Subjects who have any history of an allogeneic bone marrow, stem cell transplant, orsolid organ transplant.

• Subjects who are pregnant or breastfeeding women.

• Subjects who have consented and have undergone treatment in any other cancer relatedclinical trials withinthe past 6 months.

• Subjects who are currently in active treatment for drug abuse.

• Subjects who have received any treatment related to lung, breast, colorectal,pancreatic, or ovarian nodules, such as hormones prior to entering the study.

• Unsuitable sample for testing due to contamination, hemolysis, etc.